Novo Nordisk A/SWegovy pill sales missed estimates and CagriSema trial results delayed.
European stocks closed at a fresh all-time high on Wednesday, with the STOXX 600 ending at 657.14 points, up 0.04%. France's CAC-40 closed at 8,669.30 points, gaining 0.03%, while London's FTSE 100 finished at 10,888.30 points, up 0.08%. Germany's DAX slipped 0.29% to 26,126.30 points. The market continued to focus on robust corporate earnings despite lingering concerns over Middle East tensions. Glencore jumped 4.1% after reporting an 86% surge in first-half profit that beat expectations. Heineken rose 2.2% after its first-half profit came in ahead of forecasts. Novo Nordisk fell 4.3% even after raising its full-year sales and profit outlook, as investors worried that sales of its new Wegovy pill slightly missed estimates and that trial results for CagriSema, a next-generation obesity drug, faced delays. Novo Nordisk is striving to reclaim market share from Eli Lilly in the fast-growing obesity drug market. Although the company was Europe's most valuable listed firm in 2024, it has since lost significant market value.
Novo Nordisk A/SWegovy pill sales missed estimates and CagriSema trial results delayed.
Eli Lilly and CompanyNovo Nordisk's obesity drug setbacks may benefit Eli Lilly in the competitive market.
Glencore PLCGlencore's first-half profit surged 86%, beating expectations.
HeinekenHeineken's first-half profit came in ahead of forecasts.